Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is ...

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly’s expansion into cancer treatments.

The Trump administration has dropped a plan for insurers to provide cheap weight loss drugs to seniors through a Medicare ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

The FDA has approved the second GLP-1 pill for overweight and obesity. How does it compare to the Wegovy oral pill?

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Joining the ranks and reaching a $1 trillion valuation is a milestone. But staying there is also a challenge. Eli Lilly ( LLY ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

Eli Lilly's tirzepatide, marketed under the brand Zepbound for weight loss, is the leading therapy in this niche. But due to ...